SUVEN LIFE SCIENCES LTD. - 530239 - Submission Of Compliance Certificate Under Regulation 40(10) For The Half-Year Ended 31St March, 2020
With reference to above subject, please find enclosed Compliance Certificate for the half-year ended 31st March, 2020 issued by the Practicing Company Secretary, under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record. SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed News Release of our company titled 'Suven Life Sciences presented exploratory sub-group analyses data from Masupirdine (SUVN-502) Phase 2A Study at the Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) focus meeting 2020' SUVEN LIFE SCIENCES LTD. - 530239 - Closure of Trading Window
We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st April, 2020 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter and year ending 31st March, 2020, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is for your information and record. SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement regarding to Financial Results of the Company: Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for quarter and nine months ended December 31, 2019. The advertisements as appeared on February 14, 2020 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: http://www.suven.com/newspaperads.aspx SUVEN LIFE SCIENCES LTD. - 530239 - Suven Pharmaceuticals Ltd: For The Information Of Shareholders/Investors, We Are Furnishing The Following Information Pertaining To Suven Pharmaceuticals Limited (Resulting Company Pursuant To Scheme Of Arrangement (Demerger) As Sanctioned By Hon'Ble NCLT, Hyderabad Bench)
The Board of Directors of Suven Pharmaceuticals Limited in its meeting held today i.e. 13th February, 2020 approved the following matters: a) Considered the attached Un-Audited Standalone and Consolidated Financial Results (Post Demerger) of Suven Pharmaceuticals Ltd for the 3rd Quarter ended 31st December, 2019 b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) The Board has declared an Interim Dividend of Rs 2.50 per equity share and a onetime special dividend of Rs 2.50 per equity share of Rs 1/- each totaling to Rs 5.00 per share to the shareholders (allottees pursuant to scheme of arrangement approved by the NCLT) of Suven Pharmaceuticals Limited. The interim dividend will be paid within the stipulated time under law. Please find attached New Release and Investor Communication of our company. SUVEN LIFE SCIENCES LTD. - 530239 - Outcome Of The Board Meeting - Un-Audited Standalone And Consolidated Financial Results Of The Company (Post Demerger) Under Ind AS For The Quarter And Nine Months Ended 31St December, 2019
With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 13th February, 2020, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company (Post Demerger) under Ind AS for the quarter and nine months ended 31st December, 2019. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter and nine months ended 31st December, 2019 and b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above
Suven Life share price locked at upper circuit on potential sale of CRAMS biz
There were pending buy orders of 189,223 shares, with no sellers available. SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Friday, February 14, 2020 at 12:00 Noon IST to discuss the Un-audited Financial Results for the Q3 & 9M Financial Year 2020, to be declared on 13th February, 2020 Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated February 06, 2020 regarding the Date and Notice of Board Meeting, please find enclosed the copies of the newspaper advertisements as appeared today i.e. February 07, 2020 in Business Standard and Andhra Prabha (Telugu).